Dr. Liz Mosely and her team evaluated an integrated prevention program to address substance use, sexual assault, and sexual risk behaviors in teens called 'Teen Well Check'.
Findings suggest preliminary usability and acceptability.
Read more here: https://www.tandfonline.com/doi/full/10.1080/20008066.2022.2157933
Drug overdose is a leading cause of pregnancy-associated mortality in the US. This seminar will address the proximal and systemic contributors to reproductive and pregnancy outcomes, drawing on examples from research using health services research and implementation science methods to study persons who use substances in pregnancy.
Drs. Chang, Krans, and Miller held semistructured interviews with pregnant and postpartum women who have experienced opioid use disorder and intimate partner violence regarding their experiences seeking help with both issues.
Alice Gao, Dr. Liz Krans, and Dr. Marian Jarlenski found that later diagnosis of opioid use disorder (OUD) in pregnancy among non-White/Hispanic women partially explains the disparities in medication for opioid use disorder (MOUD) receipt in this population. Universal substance use screening earlier in pregnancy, combined with connecting patients to evidence-based and culturally competent care, is an approach that could close the observed racial-ethnic disparity in MOUD receipt.
Drs. Elizabeth Krans and Beatrice Chen evaluated the effects of increased access to immediate postpartum contraceptive implants on repeat pregnancy and contraceptive use rates among patients with opioid use disorder.
Little is known about the differential effects of COVID-19 on pregnant women with and without substance use disorders. Associate Dir. Marian Jarlenski, PhD, MPH, faculty member Elizabeth Krans, MD, MSC, and their team did a retrospective cohort study to find out.
